The Role of PET During Erlotinib Treatment to See the Responsiveness of Tumor Early in Patients With Non-small Cell Lung Cancer
1. Primary objectives:
To see whether the % change in SUVmax of a tumor with FLT-PET or FDG-PET at 7 days
after initiating erlotinib treatment compared with baseline SUVmax (ΔSUVmax) would
predict the tumor's responsiveness. And the responsiveness will be decided with the CT
scan after 6 weeks of erlotinib treatment.
2. Secondary objectives:
To compare ΔSUVmax and the degree of tumor shrinkage in longest diameter during erlotinib
To see ΔSUVmax in the tumors with stable disease. To see the time to progression and overall
survival according to ΔSUVmax. To compare the result of FDG-PET and FLT-PET.
Observational Model: Cohort, Time Perspective: Prospective
Korea : Korean Food and Drug Administration (KFDA)